BridgeMD
Tests treatment safety and results for Chronic Kidney Disease (Mild to Moderate)
Official title Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Adolescents With Early Stages of Chronic Kidney Disease
ClinicalTrials.gov ID: NCT07405216
What this study is testing
What is Dapagliflozin (10mg Tab)?
Dapagliflozin (10mg Tab) is an investigational medicine, given as an once-daily treatment applied to the skin, being studied as a potential treatment for chronic kidney disease (mild to moderate).
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Chronic kidney disease (CKD) is highly prevalent in the state of Aguascalientes, Mexico, particularly among adolescents and young adults. Epidemiologic and histologic studies suggest that this burden is largely driven by reduced nephron endowment of prenatal origin, leading to compensatory glomerular hyperfiltration, adaptive podocytopathy, and persistent albuminuria at early stages of disease.
- Phase 4: studies an already-approved treatment
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance. You may not know which one you got.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 14 to 18
You may be able to join if
- Age 14-18 years
- Residence in Aguascalientes
- Persistent albuminuria (ACR \>30 and \<300 mg/g)
- Estimated glomerular filtration rate ≥60 mL/min/1.73 m²
- No identifiable secondary cause (e.g., lupus, diabetes mellitus)
You likely can't join if
- Hypoalbuminemia
- Nephrotic syndrome
- Persistent macroalbuminuria (ACR \>300 mg/g)
- Secondary causes of CKD, including congenital anomalies of the kidney and urinary tract or polycystic kidney disease -
See the full eligibility criteria
- Age 14-18 years
- Residence in Aguascalientes
- Persistent albuminuria (ACR \>30 and \<300 mg/g)
- Estimated glomerular filtration rate ≥60 mL/min/1.73 m²
- No identifiable secondary cause (e.g., lupus, diabetes mellitus)
- Renal biopsy showing adaptive podocytopathy or perihilar focal segmental glomerulosclerosis -
- Hypoalbuminemia
- Nephrotic syndrome
- Persistent macroalbuminuria (ACR \>300 mg/g)
- Secondary causes of CKD, including congenital anomalies of the kidney and urinary tract or polycystic kidney disease -
The study team makes the final eligibility decision.
Where it's taking place
- Aguascalientes, Aguascalientes, Mexico
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 14 years to 18 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Aguascalientes, Aguascalientes, Mexico. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.